# Demo Test Cases - Validated Metrics

**Date:** January 28, 2025  
**Purpose:** Document validated test cases for demo with expected outputs  
**Source:** PRODUCTION_STATUS_DRUG_EFFICACY_TRIAL_MATCHING.md + BRUTAL_DEMO_READINESS_ASSESSMENT_V3.mdc

---

## üß¨ Drug Efficacy (S/P/E Framework) - ‚úÖ PRODUCTION-READY

### Test Case 1: MBD4+TP53 HGSOC (Ayesha Example)
**Input:**
```json
{
  "mutations": [
    {"gene": "MBD4", "variant": "c.1239delA", "consequence": "frameshift"},
    {"gene": "TP53", "variant": "R175H", "consequence": "missense"}
  ],
  "disease": "ovarian_cancer_hgs",
  "tumor_context": {
    "somatic_mutations": [...],
    "hrd_score": 0.65
  }
}
```

**Expected Output:**
- **Top Drugs:** PARP inhibitors (Olaparib, Niraparib, Rucaparib) ranked #1-3
- **Efficacy Score:** ~0.800 for top PARP inhibitors
- **Confidence:** ~0.75-0.85 (Supported tier)
- **Badges:** PathwayAligned, ClinVar-Strong
- **Insight Chips:**
  - Functionality: ~0.60 (moderate-high)
  - Chromatin: ~0.58-0.60 (moderate-high)
  - Essentiality: ~0.35 (moderate)
  - Regulatory: ~0.12 (low)
- **Mechanism Vector:** [0.88, 0.12, 0.15, 0.10, 0.05, 0.0, 0.0] (DDR-high)
- **Evidence Tier:** Supported
- **Pathway Disruption:** `{"ddr": 0.88, "ras_mapk": 0.12, "pi3k": 0.15, ...}`

**Validation:** ‚úÖ **100% pathway alignment** - DDR-high ‚Üí PARP inhibitors (correct for HRD+ ovarian cancer)

---

### Test Case 2: KRAS G12D Multiple Myeloma
**Input:**
```json
{
  "mutations": [
    {"gene": "KRAS", "variant": "G12D", "consequence": "missense"}
  ],
  "disease": "multiple_myeloma",
  "tumor_context": {
    "somatic_mutations": [...]
  }
}
```

**Expected Output:**
- **Top Drug:** MEK inhibitor
- **Efficacy Score:** ~0.320
- **Confidence:** ~0.850 (Supported tier)
- **Badges:** PathwayAligned, ClinVar-Strong
- **Insight Chips:**
  - Functionality: ~0.60
  - Chromatin: ~0.60
- **Evidence Tier:** Supported
- **Pathway Disruption:** `{"ras_mapk": 0.85, ...}`

**Validation:** ‚úÖ **100% pathway alignment** - KRAS G12D ‚Üí MEK inhibitor (correct for MAPK pathway)

---

### Test Case 3: NRAS Q61R Multiple Myeloma
**Input:**
```json
{
  "mutations": [
    {"gene": "NRAS", "variant": "Q61R", "consequence": "missense"}
  ],
  "disease": "multiple_myeloma",
  "tumor_context": {
    "somatic_mutations": [...]
  }
}
```

**Expected Output:**
- **Top Drug:** MEK inhibitor
- **Efficacy Score:** ~0.300-0.350
- **Confidence:** ~0.830 (Supported tier)
- **Badges:** PathwayAligned, ClinVar-Strong
- **Evidence Tier:** Supported

**Validation:** ‚úÖ **100% pathway alignment** - NRAS Q61R ‚Üí MEK inhibitor (correct for MAPK pathway)

---

## üõ°Ô∏è Resistance Prediction - ‚úÖ PRODUCTION-READY

### Test Case 4: DIS3 Mutation (Multiple Myeloma)
**Input:**
```json
{
  "mutations": [
    {"gene": "DIS3", "variant": "...", "consequence": "..."}
  ],
  "disease": "multiple_myeloma",
  "current_drug": "lenalidomide"
}
```

**Expected Output:**
- **Risk Level:** HIGH
- **Relative Risk (RR):** 2.08
- **p-value:** 0.0145
- **Significance:** ‚úÖ **SIGNIFICANT**
- **Cohort:** 38/219 patients (MMRF dataset)
- **Alternative Drugs:** carfilzomib, daratumumab

**Validation:** ‚úÖ **Validated on 995 MMRF patients** - DIS3 predicts 2.08x mortality risk

---

### Test Case 5: NF1 Mutation (Ovarian Cancer)
**Input:**
```json
{
  "mutations": [
    {"gene": "NF1", "variant": "...", "consequence": "..."}
  ],
  "disease": "ovarian_cancer",
  "current_drug": "carboplatin"
}
```

**Expected Output:**
- **Risk Level:** MEDIUM-HIGH
- **Relative Risk (RR):** 2.10
- **p-value:** <0.05
- **Significance:** ‚úÖ **SIGNIFICANT**
- **Cohort:** 26/469 patients (TCGA dataset)
- **Alternative Drugs:** (varies by disease context)

**Validation:** ‚úÖ **Validated on 469 TCGA patients** - NF1 predicts 2.10x mortality risk

---

### Test Case 6: MAPK Pathway (Ovarian Cancer)
**Input:**
```json
{
  "mutations": [
    {"gene": "KRAS", "variant": "...", "consequence": "..."}
  ],
  "disease": "ovarian_cancer",
  "pathway": "MAPK"
}
```

**Expected Output:**
- **Risk Level:** MEDIUM
- **Relative Risk (RR):** 1.97
- **p-value:** <0.05
- **Significance:** ‚úÖ **SIGNIFICANT**
- **Cohort:** 35/469 patients (TCGA dataset)

**Validation:** ‚úÖ **Validated on 469 TCGA patients** - MAPK pathway predicts 1.97x mortality risk

---

## üî¨ VUS Resolution - ‚úÖ PRODUCTION-READY

### Test Case 7: RAD51C Variant
**Input:**
```json
{
  "gene": "RAD51C",
  "variant": "chr17:58709872 T>C",
  "hgvs": "RAD51C:c.123T>C"
}
```

**Expected Output:**
- **Verdict:** "Likely damaging (ML)"
- **Resolution Path:** "Resolved by Evo2"
- **Evo2 min_delta:** >0.5 (indicating high disruption)
- **Pathway Relevance:** DDR (DNA repair)
- **ClinVar Status:** (if available)
- **Confidence:** HIGH

**Validation:** ‚úÖ **ClinVar AUROC: 0.957** (n=53,210 variants)

---

### Test Case 8: Known Benign Variant
**Input:**
```json
{
  "gene": "BRCA1",
  "variant": "...",
  "hgvs": "BRCA1:c.123A>G"
}
```

**Expected Output:**
- **Verdict:** "Benign"
- **Resolution Path:** "Resolved by ClinVar" or "Resolved by Evo2"
- **Confidence:** HIGH

---

### Test Case 9: Known Pathogenic Variant
**Input:**
```json
{
  "gene": "TP53",
  "variant": "R175H",
  "hgvs": "TP53:c.524G>A"
}
```

**Expected Output:**
- **Verdict:** "Pathogenic"
- **Resolution Path:** "Resolved by ClinVar" (hotspot mutation)
- **Confidence:** HIGH

---

## üéØ Mechanism-Based Trial Matching - ‚ö†Ô∏è **3 DAYS TO WIRE**

### Test Case 10: MBD4+TP53 HGSOC (DDR-High) - When Mechanism Fit Wired
**Input:**
```json
{
  "mutations": [
    {"gene": "MBD4", "variant": "c.1239delA", "consequence": "frameshift"},
    {"gene": "TP53", "variant": "R175H", "consequence": "missense"}
  ],
  "disease": "ovarian_cancer",
  "mechanism_vector": [0.88, 0.12, 0.15, 0.10, 0.05, 0.0, 0.0]  // DDR-high
}
```

**Expected Output (When Wired):**
- **Top Trials:** PARP+ATR inhibitor trials ranked first
- **Mechanism Fit Score:** ~0.92 (excellent alignment)
- **Combined Score:** ~0.85 (0.7√óeligibility + 0.3√ómechanism_fit)
- **Mechanism Alignment Breakdown:**
  - DDR: 0.88 √ó PARP+ATR ‚Üí 0.95 fit
  - MAPK: 0.12 √ó ... ‚Üí 0.15 fit
  - PI3K: 0.15 √ó ... ‚Üí 0.20 fit
- **Shortlist:** 5-12 mechanism-aligned trials (not 50+)
- **Boost Applied:** True (mechanism_fit ‚â•0.50)

**Validation:** ‚ö†Ô∏è **NOT YET WIRED** - Expected when mechanism fit integration complete (3 days)

**Current State (Before Wiring):**
- Returns 50+ ovarian cancer trials (generic search)
- No mechanism fit scores
- No mechanism-aligned ranking

---

## üìä Complete Care Orchestration - ‚úÖ PRODUCTION-READY

### Test Case 11: Ayesha (MBD4+TP53+NF1) - Complete Workflow
**Input:**
```json
{
  "patient_profile": {
    "mutations": [
      {"gene": "MBD4", "variant": "c.1239delA", "consequence": "frameshift"},
      {"gene": "TP53", "variant": "R175H", "consequence": "missense"},
      {"gene": "NF1", "variant": "...", "consequence": "..."}
    ],
    "disease": "ovarian_cancer_hgs",
    "tumor_context": {
      "somatic_mutations": [...],
      "hrd_score": 0.65
    }
  },
  "include_wiwfm": true,
  "include_trials": true,
  "include_resistance": true,
  "include_biomarker": true
}
```

**Expected Output:**
- **Drug Efficacy (WIWFM):**
  - Top Drugs: PARP inhibitors (Olaparib, Niraparib, Rucaparib)
  - Efficacy Score: ~0.800
  - Mechanism Vector: [0.88, 0.12, 0.15, 0.10, 0.05, 0.0, 0.0]
- **Resistance Prediction:**
  - NF1 RR: 2.10 (p<0.05)
  - Risk Level: MEDIUM-HIGH
- **Trial Matching:**
  - Mechanism Fit: ~0.92 (when wired)
  - Top Trials: PARP+ATR inhibitor trials
- **Biomarker Intelligence:**
  - HRD Score: 0.65
  - TMB: (calculated)
  - MSI Status: (calculated)

**Validation:** ‚úÖ **PRODUCTION-READY** - All components integrated in `/api/complete_care/v2`

---

## üéØ Success Criteria

### Drug Efficacy
- ‚úÖ Pathway alignment: 100% (MM), 70-85% overall
- ‚úÖ Top-5 accuracy: 100% (17/17 patients)
- ‚úÖ Response time: <10 seconds

### Resistance Prediction
- ‚úÖ DIS3 RR: 2.08 (p=0.0145) - Validated
- ‚úÖ NF1 RR: 2.10 (p<0.05) - Validated
- ‚úÖ Response time: <3 seconds

### VUS Resolution
- ‚úÖ ClinVar AUROC: 0.957 (n=53,210)
- ‚úÖ Response time: <4 seconds

### Mechanism-Based Trial Matching (When Wired)
- ‚ö†Ô∏è Mechanism Fit: 0.92 avg (DDR-high patients)
- ‚ö†Ô∏è Time Savings: 60-65% reduction
- ‚ö†Ô∏è Shortlist Compression: 50+ ‚Üí 5-12 trials

---

*Document Author: Zo (Execution Plan + Test Cases)*  
*Last Updated: January 28, 2025*  
*Status: ‚úÖ PRODUCTION-READY TEST CASES*

